[Therapeutic mechanism of combination therapy of ligustrazine and nitrendipine in treating patients with chronic obstructive pulmonary disease].
OBJECTIVE
To study the therapeutic mechanism of combination therapy of ligustrazine and nitrendipine in treating patients with chronic obstructive pulmonary disease (COPD).


METHODS
Thirty COPD patients divided in to 3 groups (10 in each) were treated with ligustrazine, nitrendipine and ligustrazine plus nitrendipine respectively, and the changes of hemorrheologic parameters, plasma endothelin (ET-1), thromboxane A2(TXA2) and platelet-P-selectin (CD62P) before and after treatment were observed.


RESULTS
The combination therapy of ligustrazine and nitrendipine could lower the levels of plasma ET-1, TXA2, CD62P and the hemorrheologic parameters.


CONCLUSIONS
Combination of ligustrazine and nitrendipine showed a therapeutic effect better than that of the two drugs used separately. Its effect in lowering pulmonary circulation resistance is related with the lowering of plasma vaso-contrictive factor and the changing of hemorrheologic properties. The integrated traditional Chinese and western medical therapy is valuable in treating COPD.
Lin
C L
CL
Medical Department, First People's Hospital of Yueyang, Hunan 414000.
Zhang
Z X
ZX
Xu
Y J
YJ
D000368:Aged; D004359:Drug Therapy, Combination; D019332:Endothelin-1 / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000627:therapeutic use*; D019007:P-Selectin / Q000097:blood; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood; D014665:Vasodilator Agents / Q000627:therapeutic use*
D019332:Endothelin-1; D019007:P-Selectin; D011719:Pyrazines; D014665:Vasodilator Agents; D013929:Thromboxane B2; D009568:Nitrendipine; C017953:tetramethylpyrazine